Market Overview

Global Gene Delivery Systems Industry

Share:

New York, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Gene Delivery Systems Industry" - https://www.reportlinker.com/p05960944/?utm_source=GNW
4% over the period 2020-2027. Viral Gene Delivery, one of the segments analyzed in the report, is projected to record 6.6% CAGR and reach US$3.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-viral Gene Delivery segment is readjusted to a revised 4.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $758.6 Million, While China is Forecast to Grow at 6% CAGR

The Gene Delivery Systems market in the U.S. is estimated at US$758.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$695.5 Million by the year 2027 trailing a CAGR of 6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6% and 5.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.We bring years of research experience to this 8th edition of our report. The 247-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Amgen, Inc.
  • Bayer AG
  • Human Stem Cells Institute
  • Johnson & Johnson
  • Novartis AG
  • Oxford Biomedica plc
  • Pfizer, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Sibiono GeneTech Co. Ltd.




Read the full report: https://www.reportlinker.com/p05960944/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Gene Delivery System Competitor Market Share Scenario Worldwide
(in %): 2019 & 2025
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Gene Delivery
Systems by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 2: World Historic Review for Gene Delivery Systems by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 3: World 15-Year Perspective for Gene Delivery Systems by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Viral Gene
Delivery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 5: World Historic Review for Viral Gene Delivery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 6: World 15-Year Perspective for Viral Gene Delivery by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Non-viral Gene
Delivery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 8: World Historic Review for Non-viral Gene Delivery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 9: World 15-Year Perspective for Non-viral Gene Delivery
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Infectious
Diseases by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 11: World Historic Review for Infectious Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 12: World 15-Year Perspective for Infectious Diseases by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 14: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 15: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 16: World Current & Future Analysis for CVD by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027

Table 17: World Historic Review for CVD by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019

Table 18: World 15-Year Perspective for CVD by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 19: World Current & Future Analysis for Urology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 20: World Historic Review for Urology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 21: World 15-Year Perspective for Urology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 22: World Current & Future Analysis for CNS by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027

Table 23: World Historic Review for CNS by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019

Table 24: World 15-Year Perspective for CNS by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 25: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 26: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 27: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Oral by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 29: World Historic Review for Oral by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019

Table 30: World 15-Year Perspective for Oral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 31: World Current & Future Analysis for Injectable by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 32: World Historic Review for Injectable by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 33: World 15-Year Perspective for Injectable by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Inhalation by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 35: World Historic Review for Inhalation by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 36: World 15-Year Perspective for Inhalation by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Transdermal by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 38: World Historic Review for Transdermal by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 39: World 15-Year Perspective for Transdermal by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 40: World Current & Future Analysis for Ocular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 41: World Historic Review for Ocular by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019

Table 42: World 15-Year Perspective for Ocular by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 43: World Current & Future Analysis for Nasal by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 44: World Historic Review for Nasal by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019

Table 45: World 15-Year Perspective for Nasal by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 46: World Current & Future Analysis for Other Route of
Administrations by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027

Table 47: World Historic Review for Other Route of
Administrations by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019

Table 48: World 15-Year Perspective for Other Route of
Administrations by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Gene Delivery System Market Share (in %) by Company: 2019 &
2025
Market Analytics
Table 49: USA Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 50: USA Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 51: USA 15-Year Perspective for Gene Delivery Systems by
Delivery - Percentage Breakdown of Value Sales for Viral Gene
Delivery and Non-viral Gene Delivery for the Years 2012, 2020 &
2027

Table 52: USA Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 53: USA Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 54: USA 15-Year Perspective for Gene Delivery Systems by
Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 55: USA Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 56: USA Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 57: USA 15-Year Perspective for Gene Delivery Systems by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral, Injectable, Inhalation, Transdermal, Ocular, Nasal
and Other Route of Administrations for the Years 2012, 2020 &
2027

CANADA
Table 58: Canada Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 59: Canada Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 60: Canada 15-Year Perspective for Gene Delivery Systems
by Delivery - Percentage Breakdown of Value Sales for Viral
Gene Delivery and Non-viral Gene Delivery for the Years 2012,
2020 & 2027

Table 61: Canada Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 62: Canada Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 63: Canada 15-Year Perspective for Gene Delivery Systems
by Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 64: Canada Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 65: Canada Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 66: Canada 15-Year Perspective for Gene Delivery Systems
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectable, Inhalation, Transdermal, Ocular,
Nasal and Other Route of Administrations for the Years 2012,
2020 & 2027

JAPAN
Table 67: Japan Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 68: Japan Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 69: Japan 15-Year Perspective for Gene Delivery Systems
by Delivery - Percentage Breakdown of Value Sales for Viral
Gene Delivery and Non-viral Gene Delivery for the Years 2012,
2020 & 2027

Table 70: Japan Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 71: Japan Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 72: Japan 15-Year Perspective for Gene Delivery Systems
by Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 73: Japan Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 74: Japan Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 75: Japan 15-Year Perspective for Gene Delivery Systems
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectable, Inhalation, Transdermal, Ocular,
Nasal and Other Route of Administrations for the Years 2012,
2020 & 2027

CHINA
Table 76: China Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 77: China Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 78: China 15-Year Perspective for Gene Delivery Systems
by Delivery - Percentage Breakdown of Value Sales for Viral
Gene Delivery and Non-viral Gene Delivery for the Years 2012,
2020 & 2027

Table 79: China Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 80: China Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 81: China 15-Year Perspective for Gene Delivery Systems
by Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 82: China Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 83: China Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 84: China 15-Year Perspective for Gene Delivery Systems
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectable, Inhalation, Transdermal, Ocular,
Nasal and Other Route of Administrations for the Years 2012,
2020 & 2027

EUROPE
Market Facts & Figures
European Gene Delivery System Market: Competitor Market Share
Scenario (in %) for 2019 & 2025
Market Analytics
Table 85: Europe Current & Future Analysis for Gene Delivery
Systems by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2020 through 2027

Table 86: Europe Historic Review for Gene Delivery Systems by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019

Table 87: Europe 15-Year Perspective for Gene Delivery Systems
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2020 & 2027

Table 88: Europe Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 89: Europe Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 90: Europe 15-Year Perspective for Gene Delivery Systems
by Delivery - Percentage Breakdown of Value Sales for Viral
Gene Delivery and Non-viral Gene Delivery for the Years 2012,
2020 & 2027

Table 91: Europe Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 92: Europe Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 93: Europe 15-Year Perspective for Gene Delivery Systems
by Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 94: Europe Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 95: Europe Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 96: Europe 15-Year Perspective for Gene Delivery Systems
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectable, Inhalation, Transdermal, Ocular,
Nasal and Other Route of Administrations for the Years 2012,
2020 & 2027

FRANCE
Table 97: France Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 98: France Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 99: France 15-Year Perspective for Gene Delivery Systems
by Delivery - Percentage Breakdown of Value Sales for Viral
Gene Delivery and Non-viral Gene Delivery for the Years 2012,
2020 & 2027

Table 100: France Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 101: France Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 102: France 15-Year Perspective for Gene Delivery Systems
by Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 103: France Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 104: France Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 105: France 15-Year Perspective for Gene Delivery Systems
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectable, Inhalation, Transdermal, Ocular,
Nasal and Other Route of Administrations for the Years 2012,
2020 & 2027

GERMANY
Table 106: Germany Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 107: Germany Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 108: Germany 15-Year Perspective for Gene Delivery
Systems by Delivery - Percentage Breakdown of Value Sales for
Viral Gene Delivery and Non-viral Gene Delivery for the Years
2012, 2020 & 2027

Table 109: Germany Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 110: Germany Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 111: Germany 15-Year Perspective for Gene Delivery
Systems by Application - Percentage Breakdown of Value Sales
for Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 112: Germany Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 113: Germany Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 114: Germany 15-Year Perspective for Gene Delivery
Systems by Route Of Administration - Percentage Breakdown of
Value Sales for Oral, Injectable, Inhalation, Transdermal,
Ocular, Nasal and Other Route of Administrations for the Years
2012, 2020 & 2027

ITALY
Table 115: Italy Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 116: Italy Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 117: Italy 15-Year Perspective for Gene Delivery Systems
by Delivery - Percentage Breakdown of Value Sales for Viral
Gene Delivery and Non-viral Gene Delivery for the Years 2012,
2020 & 2027

Table 118: Italy Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 119: Italy Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 120: Italy 15-Year Perspective for Gene Delivery Systems
by Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 121: Italy Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 122: Italy Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 123: Italy 15-Year Perspective for Gene Delivery Systems
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectable, Inhalation, Transdermal, Ocular,
Nasal and Other Route of Administrations for the Years 2012,
2020 & 2027

UNITED KINGDOM
Table 124: UK Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 125: UK Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 126: UK 15-Year Perspective for Gene Delivery Systems by
Delivery - Percentage Breakdown of Value Sales for Viral Gene
Delivery and Non-viral Gene Delivery for the Years 2012, 2020 &
2027

Table 127: UK Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 128: UK Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 129: UK 15-Year Perspective for Gene Delivery Systems by
Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 130: UK Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 131: UK Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 132: UK 15-Year Perspective for Gene Delivery Systems by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral, Injectable, Inhalation, Transdermal, Ocular, Nasal
and Other Route of Administrations for the Years 2012, 2020 &
2027

REST OF EUROPE
Table 133: Rest of Europe Current & Future Analysis for Gene

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05960944/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________


Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Primary Logo

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com